Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma.

scientific article published on 10 April 2013

Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VACCINE.2013.03.041
P698PubMed publication ID23583462
P5875ResearchGate publication ID236180168

P50authorEmmanuel NonyQ51070462
Didier BetbederQ57041630
P2093author name stringLaurent Mascarell
Philippe Moingeon
Sophie Tourdot
Véronique Baron-Bodo
Hélène Moussu
Véronique Bordas-Le Floch
Sabi Airouche
Nathalie Berjont
P2860cites workDose translation from animal to human studies revisitedQ29618049
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.Q34090431
Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.Q34098035
Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitisQ34521979
Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessmentQ34522246
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitisQ34569676
The future of antigen-specific immunotherapy of allergyQ34716363
Building better mouse models of asthmaQ36062587
CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthmaQ36346464
Adjuvants and vector systems for allergy vaccinesQ37870458
Animal models of asthma: value, limitations and opportunities for alternative approachesQ37896961
Local immunological mechanisms of sublingual immunotherapyQ37946147
The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice.Q39597914
Evaluation of therapeutic sublingual vaccines in a murine model of chronic house dust mite allergic airway inflammationQ39686005
Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.Q40403475
Effects of birch pollen and traffic particulate matter on Th2 cytokines, immunoglobulin E levels and bronchial hyper-responsiveness in miceQ43969563
Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.Q45275973
Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation.Q50994741
Inbred strain variation in lung function.Q51704216
Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice.Q51717643
Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction.Q51819173
Comparison of aerosol and intranasal challenge in a mouse model of allergic airway inflammation and hyperresponsiveness.Q53323233
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.Q53459403
Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression.Q53697543
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.Q53988360
PROPHYLACTIC INOCULATION AGAINST HAY FEVERQ57255078
Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparationQ58490825
Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cellsQ58854559
Mucosal tolerance induction with hypoallergenic molecules in a murine model of allergic asthmaQ73765930
Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergyQ77846802
Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cellsQ79955729
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 yearsQ80397425
Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in childrenQ80753289
Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapyQ82935339
Local nasal immunotherapy: efficacy of Dermatophagoides farinae-chitosan vaccine in murine asthmaQ83991509
Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic miceQ84580187
P433issue23
P407language of work or nameEnglishQ1860
P921main subjectpollenQ79932
asthmaQ35869
P304page(s)2628-2637
P577publication date2013-04-10
P1433published inVaccineQ7907941
P1476titleEfficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma.
P478volume31

Reverse relations

cites work (P2860)
Q26852113Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
Q38824177Allergen immunotherapy for birch pollen-allergic patients: recent advances.
Q41495360Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products
Q27700098Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients
Q98735541Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon
Q38255585Modified allergens and their potential to treat allergic disease
Q34093047Molecular biomarkers for grass pollen immunotherapy
Q38123163Multi-faceted functions of secretory IgA at mucosal surfaces
Q48169888Peptide and Recombinant Allergen Vaccines for Food Allergy
Q91741041Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-Induced Allergic Inflammation

Search more.